FEBS Letters · 2008 · 159 citations · 30 references
Life SciencesBiochemistryMolecular BiologyMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseAmyloid FormationFibrous ProteinsLigand BindingNeurodegenerative DiseasesNeurodegenerative DisordersAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid Fibril FormationAmyloid FibrillizationAmyloid FibrillogenesisAmyloid FibrilsBinding AssaysCompetitive Binding Assays
It has been suggested that transthyretin (TTR) is involved in preventing A-Beta fibrillization in Alzheimer's disease (AD). Here, we characterized the TTR/A-Beta interaction by competition binding assays. TTR binds to different A-Beta peptide species: soluble (Kd, 28 nM), oligomers and fibrils; diverse TTR variants bind differentially to A-Beta. Transmission electron microscopy (TEM) analysis demonstrated that TTR is capable of interfering with A-Beta fibrillization by both inhibiting and disrupting fibril formation. Co-incubation of the two molecules resulted in the abolishment of A-Beta toxicity. Our results confirmed TTR as an A-Beta ligand and indicated the inhibition/disruption of A-Beta fibrils as a possible mechanism underlying the protective role of TTR in AD.
30
Serum insulin-like growth factor I regulates brain amyloid-β levels
Eva Carro, José Luís Trejo, Teresa Gómez‐Isla et al. · Nature Medicine · 2002 · 449 citations
Serum insulin-like growth factor I regulates brain amyloid-β levels
Eva Carro, Trejo Jl, Teresa Gómez‐Isla et al. · Nature Medicine · 2002 · 435 citations